Seeking Alpha

Negative results from a major study of Merck's (MRK) cholesterol drug Tredaptive could spell the...

Negative results from a major study of Merck's (MRK) cholesterol drug Tredaptive could spell the end of sales of AbbVie's (ABBV) Niaspan, which is an extended-release form of the niacin vitamin that sold $911M in 2012. Niacin is used in Tredaptive along with Merk's laropiprant; Tredaptive failed to reduce strokes, deaths and heart attacks in patients with vascular diseases but did cause increased side effects. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)